Transparency and Innovation: Examining FDA Regulation at a House Energy and Commerce Committee Hearing

The House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA) and Subcommittee on Health Chair Brett Guthrie (R-KY) announced a hearing titled “Check Up: Examining FDA Regulation of Drugs, Biologics, and Devices.” The Chairs emphasized the importance of regularly engaging with FDA officials to understand what is working well and what challenges persist. They highlighted that America is a leader in developing cutting-edge biomedical innovation, with countries around the globe looking to the FDA for guidance on safe and effective treatments and medical devices. Rebuilding public trust in government health agencies, such as the FDA, will require greater transparency.

The Subcommittee on Health hearing is scheduled for Wednesday, May 22, 2024, at 10:30 AM ET at 2322 Rayburn House Office Building. The hearing will focus on discussing the FDA’s regulation of drugs, biologics, and devices. Witnesses at the hearing will include Dr. Patrizia Cavazzoni, Director of the Center for Drug Evaluation and Research (CDER) at the FDA, Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER) at the FDA, and Dr. Jeffrey Shuren, Director of the Center for Devices and Radiological Health (CDRH) at the FDA. The hearing will be open to the public and press, and will be live streamed online at https://energycommerce.house.gov/.

For questions about the hearing